Sugi Predict

Sugi Predict / Compounds / SCHEMBL342680

SCHEMBL342680

SCHEMBL342680

COc1cc(COc2[c]cccc2)ccc1CCl

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ABCB1 P08183 9/20 0.42
▸ ABCG2 Q9UNQ0 1/20 0.40
▸ TTR P02766 1/20 0.39
▸ APP P05067 1/20 0.35
▸ TUBB4A P04350 1/20 0.35
▸ TUBB P07437 1/20 0.35
▸ TUBA3C P0DPH7 1/20 0.35
▸ TUBA1B P68363 1/20 0.35
▸ TUBA4A P68366 1/20 0.35
▸ TUBB4B P68371 1/20 0.35
▸ TUBB3 Q13509 1/20 0.35
▸ TUBB2A Q13885 1/20 0.35
▸ TUBB8 Q3ZCM7 1/20 0.35
▸ TUBA3E Q6PEY2 1/20 0.35
▸ TUBA1A Q71U36 1/20 0.35
▸ TUBA1C Q9BQE3 1/20 0.35
▸ TUBB6 Q9BUF5 1/20 0.35
▸ TUBB2B Q9BVA1 1/20 0.35
▸ TUBB1 Q9H4B7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL873803 0.77 TUBB1 (0.40) ABCB1ABCG2TTRAPPTUBB4A
SCHEMBL5544217 0.77 APLNR (0.46) ABCB1
SCHEMBL3767200 0.74 IDO1 (0.51) ABCB1ABCG2
SCHEMBL2451926 0.74 APP (0.49) ABCB1APP
SCHEMBL6810250 0.73 MAOB (0.55) ABCB1
SCHEMBL342460 0.73 CYP19A1 (0.34) ABCB1ABCG2
SCHEMBL7242762 0.73 NPC1 (0.53) —
SCHEMBL4602340 0.73 ABCB1 (0.48) ABCB1APP
SCHEMBL11838721 0.71 CA2 (0.61) TTRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL15389735 0.71 LOXL2 (0.50) ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4397366-A2 GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA Ardelyx, Inc. (US) 2024-07-10 — — EP disclosed
US-20240209019-A1 COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA ARDELYX, INC. (US) 2024-06-27 — — US disclosed
EP-3682873-B1 SMAC MIMETICS FOR USE IN THE TREATMENT OF PERSISTENT HIV INFECTION WALTER & ELIZA HALL INST MEDICAL RES (AU) 2024-06-12 — — EP disclosed
US-RE49934-E1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2024-04-23 — — US disclosed
US-20240116872-A1 PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING GENENTECH, INC. (US) 2024-04-11 — — US disclosed
EP-3661945-B1 GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA ARDELYX INC (US) 2024-04-03 — — EP disclosed
US-11858959-B2 Glycyrrhetinic acid derivatives for use in treating hyperkalemia ARDELYX, INC. (US) 2024-01-02 — — US disclosed
US-11768319-B2 Glycyrrhetinic acid derivatives for treating hyperkalemia ARDELYX, INC. (US) 2023-09-26 — — US disclosed
US-20230273354-A1 GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA ARDELYX, INC. (US) 2023-08-31 — — US disclosed
EP-4234016-A2 GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA Ardelyx, Inc. (US) 2023-08-30 — — EP disclosed
US-20040158076-A1 Tyrosine derivatives GENENTECH, INC. 2004-08-12 — — US disclosed
US-20040110753-A1 Tyrosine derivatives GENENTECH, INC. 2004-06-10 — — US disclosed
US-20030212071-A1 Serine protease inhibitors GENENTECH, INC. 2003-11-13 — — US disclosed
US-6472393-B1 Serine protease inhibitors GENENTECH, INC. 2002-10-29 — — US disclosed
US-6469047-B1 NON-PROTEIN SMALL MOLECULE COMPOUNDS WHICH INHIBIT THE INTERACTION BETWEEN THE ALPHA 4 BETA 7 INTEGRIN AND ITS LIGANDS MADCAM AND/OR VCAM. THESE COMPOUNDS ARE USEFUL FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SUCH AS ARTHRITIS GENENTECH, INC. 2002-10-22 — — US disclosed
EP-1214292-A1 TYROSINE DERIVATIVES Genentech, Inc. (US) 2002-06-19 — — EP disclosed
EP-1144373-A3 SERINE PROTEASE INHIBITORS Genentech, Inc. (US) 2002-01-02 — — EP disclosed
EP-1144373-A2 SERINE PROTEASE INHIBITORS Genentech, Inc. (US) 2001-10-17 — — EP disclosed
WO-2001021584-A1 TYROSINE DERIVATIVES GENENTECH, INC. (US) 2001-03-29 — — WO disclosed
WO-2000041531-A2 SERINE PROTEASE INHIBITORS GENENTECH, INC. (US) 2000-07-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212071-A1 Serine protease inhibitors SERPINE1, SPINT2, TFPI ABCB1 4093/4885ABCG2 2467/4885TTR 1034/4885
US-20240209019-A1 COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA REN, NHERF1, KCNJ11 ABCB1 899/4885ABCG2 678/4885TTR 2177/4885
US-20240116872-A1 PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING SHH, GLI1, SMO ABCB1 2928/4885ABCG2 2412/4885TTR 4822/4885
US-11768319-B2 Glycyrrhetinic acid derivatives for treating hyperkalemia HSD11B2, HSD11B1, HSD3B2 ABCB1 1613/4885ABCG2 2387/4885TTR 3759/4885
US-20040110753-A1 Tyrosine derivatives VCAM1, ICAM1, ITGB4 ABCB1 362/4885ABCG2 874/4885TTR 2387/4885
US-20230273354-A1 GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA GRHPR, REN, GRK5 ABCB1 1853/4885ABCG2 1845/4885TTR 2046/4885
US-11858959-B2 Glycyrrhetinic acid derivatives for use in treating hyperkalemia HSD11B2, HSD11B1, NR3C2 ABCB1 1763/4885ABCG2 2132/4885TTR 3193/4885
US-20040158076-A1 Tyrosine derivatives VCAM1, ICAM1, ITGB4 ABCB1 362/4885ABCG2 874/4885TTR 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.